ASCO® 2025 Highlights: Presenter Vignette – Janice Mehnert

Dr. Janice Mehnert

Janice Mehnert

MD

NYU Grossman School of Medicine

9510

A phase II study of the interleukin-6 (IL-6) receptor blocking antibody sarilumab (Sari) in combination with ipilimumab (Ipi), nivolumab (Nivo) and relatlimab (Rela) in patients with unresectable stage III or stage IV melanoma.

Interested in learning more about these abstracts and other trials presented at ASCO® 2025? Be sure to register for one of our licensed Best of ASCO® events in a city near you.

This program has been made possible through unrestricted support from Boehringer Ingelheim, Eli Lilly and Ipsen